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ABSTRACT The identification of acquired homozygosity
in human cancers implies locations of tumor suppressor genes
without providing functional evidence. The loalization of a
defect in embryonal rhabdomyosarcomas to chromosomal re-
gion llpl5 provides one such example. In this report, we show
that transfer of a normal human chromosome 11 into an
embryonal rhabdomyosarcoma cell line elicited a dramatic loss
of the proliferative capacity of the transferrants. Indeed, the
majority of the viable microcell hybrids had either eliminated
genetic information on the short arm of the transferred chro-
mosome 11 or increased the copy number of the rhabdomyo-
sarcoma-derived chromosomes 11. Cells that possessed only the
long arm of chromosome 11 also demonstrated a decreased
growth rate. In contrast, all microcell hybrids retained the
ability to form tumors upon inoculation into animals. These
functional data support molecular studies indicating loss of
genetic information on chromosome 11p15 during the devel-
opment of embryonal rhabdomyosarcoma. In addition, our
studies demonstrate the existence of a second gene on the long
arm, previously unrecognized by molecular analyses, which
negatively regulates the growth of embryonal rhabdomyosar-
coma cell lines.
The development of human neoplasia appears to entail a
sequential series of genetic alterations followed by clonal
expansion (1). Some of these steps can consist of the acti-
vation of oncogenes or the loss of tumor suppressor gene
function. While more than 40 oncogenes have been identified,
fewer than 10 tumor suppressor genes have been character-
ized (2-12). Knowledge of the existence of the latter class of
genes relies mainly upon indirect or circumstantial evidence
derived from somatic cell hybridization, cytogenetic analy-
ses, and tumor-specific loss ofnearby molecular markers (13,
14). With little functional evidence to support data showing
their physical locations in the human genome, isolation of
tumor suppressor genes remains an arduous task.
One approach to this problem uses the technique of mi-
crocell hybridization to transfer a single chromosome from a
normal somatic cell into a human tumor cell line (15, 16). We
have previously shown a loss of tumorigenic potential after
introduction of a normal human chromosome 11 into a Wilms
tumor-derived cell line consonant with cytogenetic studies
and restriction fragment length polymorphism (RFLP) map-
ping demonstrating deletions or homozygosis ofchromosome
11 in several Wilms tumors (17-19). Recently, cytogenetic
evidence of deletions in the long arm of chromosome 6 in
melanomas led to a demonstration of suppression of tumor-
igenicity in human melanoma cells by the introduction of that
chromosome (20). Similar studies showed suppression of
tumorigenicity in a renal cell carcinoma line after introduc-
tion of chromosome 3, consistent with cytogenetic abnor-
malities in the corresponding tumors (21).
Each of these microcell hybridization studies on suppres-
sion of tumorigenicity depended on visible chromosome
deletions to identify which chromosome might carry a tumor
suppressor gene. In many cases, location of putative tumor
suppressor genes relies on molecular evidence alone. For
example, embryonal rhabdomyosarcoma, a pediatric tumor
of striated muscle, carries no consistent visible cytogenetic
abnormality. However, molecular analysis of such tumors
has implicated a loss of genetic elements at chromosome
11p15.5 as a crucial event in its etiology (22, 23). To deter-
mine whether these genetic events also entailed loss of a
tumor suppressor function, we introduced a normal human
chromosome 11 into an embryonal rhabdomyosarcoma cell
line. The results suggest that loss of two different growth
suppressor genes, present on either arm of chromosome 11,
contributes to the development of embryonal rhabdomyo-
sarcoma.
MATERIAL AND METHODS
Cell Lines. The RD cell line is a well-characterized embry-
onal rhabdomyosarcoma cell line derived from the tumor of
a 7-year-old patient (24). HDM-18 is a 3T6 mouse cell
containing a single human chromosome 11 with an integrated
copy of the neomycin resistance (neoR) gene at 11q14-q22
(25). The neoll/A9neo line retains a different human chro-
mosome 11 with an integrated copy ofthe neoR gene at 11p12,
while the neo2/A9 donor line contains a single human chro-
mosome 2 with an integrated copy of the same gene (26, 27).
All cell lines were grown in Dulbecco's modified Eagle's
medium (DMEM) containing 10% fetal calf serum and pen-
icillin at 100 units/ml. Each cell line was routinely tested for
mycoplasma infection and found to be negative (28).
Microcell Hybridization and Gene Transfer. Microcell hy-
bridization was performed as previously described (17) with
the following exception. The flasks were coated with poly(D-
lysine) at 5 ,ug/ml for the HDM-18 cell lines to improve the
number of microcells. Introduction of the pMAMneo-1 vec-
tor (Clontech) into the RD cells was accomplished by the use
of Lipofectin reagent (GIBCO/BRL). Selection of neoR
microcell hybrids and transfectants was carried out in growth
medium containing G418 (GIBCO/BRL) at 600 ,g/ml. Indi-
vidual colonies were selected by the use of glass cloning
cylinders and expanded for further characterization.
Abbreviations: RFLP, restriction fragment length polymorphism;
neoR, neomycin resistance or resistant.
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Growth Curves. The population doubling time of each cell
line was determined by measuring the growth rate over a 7-
to 10-day period. Each cell line was plated into 60-mm Petri
dishes at 5 x 104 cells per dish in growth medium and allowed
to incubate overnight. Cell number was measured in 3 dishes
the next day (day 0) and on days 1, 3, 5, 7, and 10 by using
a Coulter Counter. All cells were fed every 3 days with
growth medium. Population doubling times represent the
average of at least two experiments. The population doubling
time was calculated by using the formula population doubling
time = (t2 - t1)/3.32 log(X2/X1), where X,, represents the cell
number at time t,. The t values used were day 3 and day 5,
covering the logarithmic phase of growth for each cell line.
Cytogenetic Analyses. The karyotypes of the RD cell line
and the microcell hybrids were determined by Giemsa-
trypsin banding as previously described (17). At least 10
metaphase spreads were examined for each cell line.
Analyses of RFLP Markers. The presence of the alleles for
three chromosome 11 molecular probes was determined by
Southern blotting as previously described (23). Probes were
labeled by random priming methods using isolated inserts
(23).
RESULTS
Isolation ofRD Microcell Hybrids Containing Human Chro-
mosome 11. We initially tried to transfer chromosome 11 from
the HDM-18 cell line into the RD cells. In five separate
experiments, we isolated few viable microcell hybrids. Most
colonies that arose after fusion became quiescent after ap-
proximately 10 population -doublings. These findings sug-
gested that a suppressor gene for cellular immortality might
reside on chromosome 11. However, transfer ofchromosome
2 or 6 into the RD cells yielded similar results; most of the
colonies failed to proliferate beyond a 1-cm diameter. In
many cases, the microcell hybrids contained a near-tetraploid
chromosome number, while the RD cell line displayed a




documented gene-dosage effects on the control of tumorige-
nicity in somatic cell hybrids, we chose to characterize only
near-diploid microcell hybrids for potential alterations in
growth properties (21, 29, 30).
Cytogenetic Analysis of the HDM-18/RD Microcell Hy-
brids. The generation of microcell hybrids frequently causes
rearrangements and translocations of individual chromo-
somes, including the transferred chromosome. This raised
the possibility that viable near-diploid microcell hybrids
might arise subsequent to the loss of a gene in the introduced
chromosome capable ofinhibiting growth. To test the validity
ofthis scenario, we performed a detailed cytogenetic analysis
of the RD parent and pseudodiploid microcell hybrids con-
taining chromosome 2 or 11. The RD cell line displayed a
pseudodiploid karyotype with a mode of 47 chromosomes,
including two normal-appearing chromosomes 11 (Fig. 1).
A microcell hybrid containing chromosome 2 showed an
additional copy of this chromosome (data not shown). In
contrast, all three of the HDM-18/RD microcell hybrids
possessed a similar karyotype without an additional copy of
the chromosome 11 indicative of the neoR-selectable trans-
ferred material. Each of the clones did carry new chromo-
some 11 rearrangements. The HDM-18/RD.1 cell line's kary-
otype included a new marker chromosome containing the
long arm of chromosome 11, while the other two cell lines
possessed an iso(11q) chromosome (Fig. 1). Thus, the rare
appearance of viable pseudodiploid microcell hybrids after
introduction of a normal chromosome 11 appeared to require
the loss of the short arm.
Detection of the Normal Chromosome 11 in the HDM-
18/RD Cells by RFLP Markers. While these data suggested
that the rearranged chromosomes 11 in the microcell hybrids
were derived from the transferred chromosome 11, cytoge-
netic analysis could not establish their origins. We, therefore,
carried out a molecular analysis of the RD cell line and the
microcell hybrids, using RFLP markers on both arms of
chromosome 11. Analysis with the probe pE46-TGH2, which
hybridizes to the locus DIIS24 on the long arm, confirmed
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FIG. 1. Cytogenetic analysis of the RD cell line and the microcell hybrids. The karyotypes of the RD cell line and the microcell hybrids were
determined by Giemsa-trypsin banding (17). At least 10 metaphase spreads were examined for each cell line. The presumed rearranged
chromosome 11 that was introduced into the RD cells is denoted with an arrow.
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the presence of the introduced chromosome in the majority
of cells of each microcell hybrid (Fig. 2). Furthermore, the
stoichiometry of alleles at D 1524 appears to resemble that
in normal diploid cells. On the short arm, however, analysis
at the 8-globin HBBC and HRASI loci in 11p15.5 revealed
that the alleles contributed specifically by the introduced
chromosome 11 failed to appear in each of the hybrids. Thus,
at HBBC, a majority of cells lost the 3.5-kb allele at the yA
locus contributed by the normal chromosome 11, and at
HRASJ virtually all cells were missing the 0.9-kb allele from
the same chromosome. These data support the notion that the
marker chromosomes arose from a rearrangement of the
introduced chromosome 11.
In Vito and in Vivo Growth Properties of the HDM-18/RD
Cell Lines. Despite the loss of the genetic information on the
short arm of the normal chromosome 11, it appeared that the
microcell hybrids differed from the parental RD cells in both
morphology and growth rate. We, therefore, characterized the
in vitro and in vivo growth characteristics of the RD cells and
the microcell hybrids. The presence of the extra copy of the
long arm of chromosome 11 resulted in a more elongated
morphology and an increased number of spindle-shaped cells
(data not shown). The microcell hybrids also demonstrated a
decreased growth rate compared with the RD parental cells,
ranging from slight (HDM-18/RD.2) to substantial (HDM-18/
RD.3) (Table 1). In contrast, transfer ofa plasmid carrying the
neoR gene (neo/RD.1) or a normal human chromosome 2
(neo2/RD.1 and neo2/RD.2) into the RD cells had no effect on
their growth (Table 1) or their morphology (data not shown).
However, the decrease in the growth of the microcell hybrids
in vitro did not correspond to a reduced tumorigenic potential
in nu/nu (nude) mice (Table 1). Although a range of tumori-
genic potentials existed among the various microcell hybrids,
no correlation was observed between retarded growth in
culture and reduced tumorigenicity in vivo (Table 1).
An alternative explanation for the tumorigenicity results
above might be that the introduced chromosome was lost












FIG. 2. RFLP analyses of chromosome 11 markers for the RD
cell line and the microcell hybrids. The presence of the alleles for
three chromosome 11 molecular probes was determined by Southern
blotting. Probe pE4b-TGH2 is homologous to the D11S24 locus
mapped to 11q22-23 and reveals alleles of 1.2 and 0.9 kilobases (kb)
as well as a constant band (c) at 0.95 kb with Rsa 1 (22, 31). This band
is obscured when the smaller allele is present. The probe JW151 is
homologous to the f,-globin gene cluster and reveals alleles of 3.5 and
2.7 + 0.8 kb at the yA locus with HindIII (32). Probe pEJ 6.6 is
homologous to the HRASI gene and detects various-sized Msp I
fragments depending on the size of the variable number of terminal
repeats region of the gene (33).
Table 1. In vitro and in vivo growth potentials of the RD cells
and the microcell hybrids
Chromo- Population No. of
some doubling cells Tumorigenic
Cell line introduced time, days injected potential
RD 0.97 ± 0.08 1 x 107 6/7 (1 wk)
1 x 106 6/10 (2 wk)
1 x 105 7/10 (5 wk)
neo/RD.1 1.00 ± 0.05 NT
Near-diploid
HDM-18/RD.1 11 1.54 ± 0.08 1 x 107 9/10 (2 wk)
1 x 106 8/8 (3 wk)
1 x 10 4/8 (5 wk)
HDM-18/RD.2 11 1.14 ± 0.01 1 x 107 10/11 (2 wk)
1 x 106 6/6 (3 wk)
1 x 105 6/12 (6 wk)
HDM-18/RD.3 11 1.80 ± 0.07 1 x 107 7/8 (3 wk)
1 x 106 12/15 (4 wk)
1 x 105 1/15 (12 wk)
neoll/RD.1 11 2.09 ± 0.10 1 x 107 5/6 (6 wk)
1 x 106 0/6
neo2/RD.1 2 0.88 ± 0.03 1 x 107 5/6 (1 wk)
1 x 106 5/6 (12 wk)
1 X 105 0/6
Near-tetraploid
HDM-18/RD.4 11 1.41 ± 0.05 NT
neoll/RD.2 11 1.42 ± 0.06 1 x 107 NT
1 x 106 5/6 (3 wk)
1 x 105 1/6 (6 wk)
neo2/RD.2 2 0.80 ± 0.02 NT
The population doubling time was derived from growth curves; the
data represent the averages from three experiments for each cell line
and the ranges of observed values. Tumorigenic potential was
assayed by subcutaneous inoculation into two sites on BALB/c
nu/nu (nude) mice with inocula sizes of 1 x 105, 1 x 106, and 1 x 107
cells. Animals were examined weekly for tumor growth and distress.
When tumors reached a size of 1 cm, they were excised, reestab-
lished into tissue culture, and characterized for cytogenetic changes.
The results are expressed as the number ofanimals positive for tumor
growth/the number of animals injected with cells. The value in
parentheses represents the average time for the appearance of tumor
nodules on the animals. Tumor growth was considered negative after
6 months. NT, not tested.
ined that possibility by reestablishing cell lines in culture
from the tumors formed by the HDM-18/RD.2 cell line, the
cell line showing the least reduction in growth rate (Table 1).
Cytogenetic analysis of this cell line, designated RD.2 TR1,
showed the presence of the iso (llq) chromosome in the
majority of the cells, yet they grew with the same population
doubling time as the parent cells (data not shown). All of
these data together support the contention that the addition
of the long arm of chromosome 11 to the RD cells caused a
decrease in growth potential in culture but not in animals.
The Short Arm of Chromosome 11 Contains a Potent
Growth-Suppressor Gene That Operates in a Dose-Dependent
Fashion. The fact the neoR marker was stably integrated into
the long arm of the chromosome 11 in the HDM-18 donor cell
might have facilitated the loss of the short arm. We, there-
fore, introduced a different chromosome 11 into the RD cell
line with the neoR plasmid integrated at 11p12 (26). Again, the
majority of microcell hybrids arising after monochromosome
transfer contained a near-tetraploid chromosome number.
However, one cell line, designated neoll/RD.1, showed
three copies of chromosome 11 by cytogenetic analysis (Fig.
3A). This cell line grew very poorly in culture, more slowly
than any of the original set ofRD microcell hybrids, and was
less tumorigenic (Table 1). RFLP analysis has confirmed the
presence of the introduced chromosome 11, including the
HRAS locus (Fig. 3B). Again, cytogenetic analysis of the
Medical Sciences: Loh et al.
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FIG. 3. Cytogenetic and RFLP analysis of the neoll/RD.1 cell
line. (A) The karyotype of the neoll/RD.1 cell line was determined
by Giemsa-trypsin banding (14). At least 10 metaphase spreads were
examined. (B) The presence of the HRASJ allele for chromosome 11
was determined by Southern blotting. The probe pEJ 6.6 is homol-
ogous to the HRASI gene and detects various-sized Msp I fragments,
depending on the size of the variable number of terminal repeats
region of the gene (33).
tumor formed by these cells demonstrated the retention of the
extra chromosome 11 (data not shown). We interpret these
results as cytogenetic support for the molecular evidence for
the presence of a potent growth-suppressor gene on the short
arm of chromosome 11. These data also support the concept
that a distinct growth suppressor gene for embryonal rhab-
domyosarcomas maps to the long arm ofhuman chromosome
11.
We initially characterized only those microcell hybrids that
retained the near-diploid karyotype to avoid the possibility of
gene-dosage effects. We have also examined two near-
tetraploid microcell hybrids with chromosome 11 and a
near-tetraploid hybrid carrying a transferred chromosome 2
(Table 1). The cell lines with a 4:1 ratio of the RD chromo-
somes 11 to the normal one grew as poorly as one of the
near-diploid microcell hybrids (Table 1). In contrast, a near-
tetraploid RD cell line containing a normal chromosome 2
grew slightly faster than the RD cell line (neo2/RD.2).
Therefore, the growth suppressor genes on chromosome 11
could also exert their effects on cell lines with additional
copies of the parental chromosome 11.
DISCUSSION
Several previous studies have demonstrated a functional
correspondence between a particular chromosome deletion
and the tumor suppressing activity of that region by microcell
hybridization (17, 20, 21). Here, we have shown that loss of
heterozygosity can also provide signposts for monochromo-
some transfer studies in the absence of visible cytogenetic
alterations. Such analyses of embryonal rhabdomyosarcoma
tumors suggested that loss of genetic material at chromosome
lipi5 was central in their development (22, 23). This report
provides functional evidence that this region contains a gene
that affects cellular proliferation in this lineage. Furthermore,
we unexpectedly detected a second gene on chromosome 11
that retarded the growth oftumor cells derived from this type
of cancer. Interestingly, this chromosome carried genes that
inhibited the proliferation of the embryonal rhabdomyosar-
coma cell line without completely suppressing tumorigenic-
ity. For the purposes of this discussion, we will use "tumor
suppressor gene" as a general term for recessive cancer
genes and "growth suppressor gene" to denote the functions
we have mapped to chromosome 11.
Several different studies have suggested that the develop-
ment of embryonal rhabdomyosarcomas and Wilms tumors
may share common steps. Patients with Beckwith-
Weidemann syndrome have an increased propensity to de-
velop embryonal cancers, including rhabdomyosarcomas
and Wilms tumors (34). Loss of heterozygosity for chromo-
some 11 occurs in both types of these tumors (19, 35).
Furthermore, mitotic recombination mapping studies have
implicated the presence of a suppressor gene in the region of
lipiS in both Wilms tumor and rhabdomyosarcomas (22, 36,
37). Our previous studies showed that introduction of a
normal human chromosome 11 into a Wilms tumor cell line
resulted in complete suppression of tumorigenicity without
any apparent effects on in vitro growth properties (17). In
contrast, gene(s) present on the same chromosome altered
the growth of an embryonal rhabdomyosarcoma cell line in
culture but not in animals. Thus, the same gene that causes
suppression of tumorigenicity in one cancer (Wilms tumor)
may function differently in a related cancer (embryonal
rhabdomyosarcoma). Alternatively, these diverse effects
may result from the action of other tumor suppressor genes
on chromosome 11. Three other tumor suppressor genes have
been mapped to this chromosome-two Wilms tumor sup-
pressor genes at 11p13 and the HeLa tumor suppressor gene
on the long arm (7, 8, 38, 39). Until the isolation of all these
recessive cancer genes, their functions in the development of
different tumors will remain elusive.
The effect on the growth of RD cells due to the presence
of the long arm of chromosome 11 was unexpected, as
previous molecular and cytogenetic studies did not implicate
a recessive cancer gene at this location. However, alternative
explanations exist, including the presence of a normal neg-
ative growth regulatory element whose extra copy decreases
the rate of cellular proliferation in the RD cells. We feel that
this is unlikely, as the decreased doubling time of the micro-
cell hybrids remained stable over long periods in culture in
the presence of the selective agent. If the parental chromo-
somes 11 contained normal copies of a negative growth
regulatory gene, loss of either parental chromosome would
restore the normal growth rate. However, this event failed to
occur over long periods in culture even though no selective
pressure for retention of these chromosomes existed.
Somatic cell hybridization studies have provided evidence
for two functionally different classes of tumor suppressor
genes. The original tumor suppressor genes regulate the
growth of tumor cells in animals without affecting their
behavior in culture, while a second class consists of genes
that control immortality or senescence (13,40). The microcell
hybrids that retained the long arm ofchromosome 11 showed
an increased doubling time in culture without consistent
effects on their tumorigenic potential in nude mice. The
microcell hybrid that possessed the entire chromosome 11
showed a 2-fold increase in cell doubling time in culture and
an increased latency period for tumor formation upon inoc-
ulation in animals. These data suggest that suppressor genes
exist that negatively regulate the proliferation of cells both in
animals and in culture or perhaps accentuate the activity of
the other classes of tumor suppressor genes. As more reces-
sive cancer genes become available for analysis, functional
differences will likely fall into sharper focus.
The apparent effects of the genetic information at ilpiS
resemble those of p53 in several fashions. Transfer of the
A
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wild-type p53 gene into human cell lines with an abnormal
gene causes a profound inhibition of growth in vitro (41, 42)
and in vivo (43). Second, the phenotype of the p53 profile
depends on the balance between normal and mutant copies of
the gene-i.e., a gene-dosage effect. A wide range of human
tumors show loss of heterozygosity at the HRAS locus,
suggesting that a p53-like gene may reside near the HRAS
gene (44). Recently, several groups have correlated germ-line
alterations in the p53 gene with the Li-Fraumeni syndrome
(45, 46). If the growth suppressor gene on chromosome lip
functions in a similar manner, it may participate in an early
step in rhabdomyosarcoma development, accounting for its
potent growth suppressing activity.
While the microcell hybridization technique maps func-
tions to whole chromosomes, this approach may provide an
advantage over single gene transfers in cases where two
genes are required for tumor suppression. Thus, if the two
suppressor genes for rhabdomyosarcoma function in tandem
to cause suppression of growth, transfer of the gene on the
short arm alone might have little effect. This hypothesis can
be tested and the region on the long arm that contains the
other suppressor gene can be identified by developing chro-
mosome 11 fragments for transfer into the RD cells. Use of
these smaller segments of chromosome 11 should lead to the
precise location of these genes, a necessary step for their
isolation by reverse genetics.
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